Herantis Pharma Oyj Cash Flow-to-Debt Ratio
Herantis Pharma Oyj cash flow-to-debt ratio. Herantis Pharma Oyj (HRTIS) has a Cash Flow-to-Debt Ratio of -1.01x as of June 2025, meaning its operating cash flow of €-3.39 Million could theoretically repay -1% of its total liabilities (€3.36 Million) in one year. Check Herantis Pharma Oyj earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Herantis Pharma Oyj (2012–2024)
Cash flow-to-debt ratio of Herantis Pharma Oyj from 2012 to 2024. Historical debt coverage capacity for Herantis Pharma Oyj across 13 annual periods. Check Herantis Pharma Oyj (HRTIS) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Herantis Pharma Oyj Cash Flow-to-Debt Ratio by Year (2012–2024)
Herantis Pharma Oyj cash flow-to-debt ratio by year from 2012 to 2024. Year-by-year debt coverage analysis for Herantis Pharma Oyj. For the full cash flow conversion analysis, see HRTIS cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (EUR) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -2.33x | €-6.54 Million | €2.81 Million | ▼ -1.3% |
| 2023 | -2.30x | €-4.64 Million | €2.02 Million | ▼ -61.5% |
| 2022 | -1.42x | €-8.94 Million | €6.29 Million | ▲ +8.9% |
| 2021 | -1.56x | €-9.93 Million | €6.36 Million | ▼ -61.1% |
| 2020 | -0.97x | €-8.56 Million | €8.83 Million | ▼ -50.0% |
| 2019 | -0.65x | €-5.96 Million | €9.22 Million | ▼ -25.3% |
| 2018 | -0.52x | €-3.73 Million | €7.24 Million | ▼ -48.5% |
| 2017 | -0.35x | €-2.60 Million | €7.48 Million | ▲ +1.2% |
| 2016 | -0.35x | €-3.04 Million | €8.63 Million | ▲ +61.5% |
| 2015 | -0.91x | €-7.40 Million | €8.09 Million | ▼ -63.1% |
| 2014 | -0.56x | €-4.36 Million | €7.77 Million | ▼ -530.5% |
| 2013 | -0.09x | €-224.21K | €2.52 Million | ▲ +63.1% |
| 2012 | -0.24x | €-533.42K | €2.21 Million | — |